---
figid: PMC9127157__fendo-13-863541-g005
figtitle: Emerging Roles and Therapeutic Implications of Epigenetic Modifications
  in Ovarian Cancer
organisms:
- Homo sapiens
- Mus musculus
- prion
pmcid: PMC9127157
filename: fendo-13-863541-g005.jpg
figlink: /pmc/articles/PMC9127157/figure/f5/
number: F5
caption: Targeting the OC epigenome and overcoming drug resistance in OC. (A) Platinum
  therapy combined with DNA methyltransferase inhibitors (DNMTis) and histone deacetylation
  inhibitors (HDACis) has been used for chemotherapeutic sensitization. (B) Overcoming
  OC drug resistance by targeting certain ncRNAs. (C) DNMTi and HDACi increased the
  responsiveness of OC to immune checkpoint therapy by reducing the immunosuppressive
  milieu via the type I IFN signaling pathway. PT, platinum; 5-aza-dC, 5-aza-2-deoxy-cytidine;
  HMA, hypomethylating agent; PD-1, programmed death protein 1; PD-L1, programmed
  death ligand 1.
papertitle: The Emerging Roles and Therapeutic Implications of Epigenetic Modifications
  in Ovarian Cancer.
reftext: Yu Wang, et al. Front Endocrinol (Lausanne). 2022;13:863541.
year: '2022'
doi: 10.3389/fendo.2022.863541
journal_title: Frontiers in Endocrinology
journal_nlm_ta: Front Endocrinol (Lausanne)
publisher_name: Frontiers Media S.A.
keywords: ovarian cancer | drug resistance | cancer epigenetics | DNA methylation
  | histone modifications | non-coding RNA | epigenetic therapy
automl_pathway: 0.9423237
figid_alias: PMC9127157__F5
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC9127157__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9127157__fendo-13-863541-g005.html
  '@type': Dataset
  description: Targeting the OC epigenome and overcoming drug resistance in OC. (A)
    Platinum therapy combined with DNA methyltransferase inhibitors (DNMTis) and histone
    deacetylation inhibitors (HDACis) has been used for chemotherapeutic sensitization.
    (B) Overcoming OC drug resistance by targeting certain ncRNAs. (C) DNMTi and HDACi
    increased the responsiveness of OC to immune checkpoint therapy by reducing the
    immunosuppressive milieu via the type I IFN signaling pathway. PT, platinum; 5-aza-dC,
    5-aza-2-deoxy-cytidine; HMA, hypomethylating agent; PD-1, programmed death protein
    1; PD-L1, programmed death ligand 1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Dnmt1
  - Mir181a-2
  - Ctnnb1
  - ac
  - Nfkb1
  - Pik3r1
  - Ifng
  - Cd274
  - Pdcd1
  - Hotair
  - Hoxa7
  - Pt
  - Hma
  - Brca1
  - DNMT1
  - DNMT3A
  - DNMT3B
  - DNMT3L
  - HDAC9
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC6
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - ATOH7
  - CTNNB1
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - LEF1
  - TCF7
  - TCF7L1
  - TCF7L2
  - HNF4A
  - NFKB1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - IFNG
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - HOTAIR
  - HOXA7
  - BRCA1
---
